Lanting Yang

Lanting Yang

Auto-generated profile, based on publicly available information

Lanting Yang

University of California San Diego

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 April 2020 in The American Journal of Cardiology
Verified
Journal Article
Closed access
LYLanting Yang
Lanting Yang
MBMaria M. Brooks
Maria M. Brooks
Nancy W GlynnNancy W Glynn
Nancy W Glynn
YZYuting Zhang
Yuting Zhang
SSSamir Saba
Samir Saba
IHInmaculada Hernandez
Inmaculada Hernandez

19 February 2021 in Pharmacoepidemiology and Drug Safety
Verified
Journal Article
Closed access
PDF file
LYLanting Yang
Lanting Yang
NGNico Gabriel
Nico Gabriel
IHInmaculada Hernandez
Inmaculada Hernandez
AWAlmut G. Winterstein
Almut G. Winterstein
JGJingchuan Guo
Jingchuan Guo

1 November 2023 in Journal of Managed Care & Specialty Pharmacy
Verified
Journal Article
Closed access
LYLanting Yang
Lanting Yang
NGNico Gabriel
Nico Gabriel
JBJiang Bian
Jiang Bian
LBLori A. Bilello
Lori A. Bilello
DWDavene R. Wright
Davene R. Wright
JGJingchuan Guo
Jingchuan Guo
BACKGROUND: Sodium-glucose cotransporter 2 inhibitors (SGLT2is) are known to improve cardiovascular and renal outcomes in patients with type 2 diabetes (T2D). Understanding the longitudinal pattern... Plain language summary Consistently taking antidiabetic treatment is crucial for patients with type 2 diabetes (T2D). This real-world study looked at how well patients took their medications during... Implications for managed care pharmacy Four distinct adherence patterns of SGLT2is were identified in a cohort of Medicare beneficiaries with T2D. Efforts to improve adherence to SGLT2is in patient...

24 November 2021 in Journal of Managed Care & Specialty Pharmacy
Verified
Journal Article
Closed access
LYLanting Yang
Lanting Yang
JGJingchuan Guo
Jingchuan Guo
QLQingfeng Liang
Qingfeng Liang
TNTerri V Newman
Terri V Newman
WGWalid F Gellad
Walid F Gellad
IHInmaculada Hernandez
Inmaculada Hernandez
BACKGROUND: Oral anticoagulation (OAC) is recommended for the prevention of stroke in atrial fibrillation (AF). However, only 50%-60% of AF patients in the United States are treated with OAC, and 6...

8 December 2023 in BMC Cardiovascular Disorders
Verified
Journal Article
Open access
PDF file
LYLanting Yang
Lanting Yang
STShangbin Tang
Shangbin Tang
MHMeiqi He
Meiqi He
JGJingchuan Guo
Jingchuan Guo
NGNico Gabriel
Nico Gabriel
IHInmaculada Hernandez
Inmaculada Hernandez
Background: The COVID-19 pandemic profoundly disrupted the delivery of medical care. It remains unclear whether individuals diagnosed with new onset disease during the pandemic were less likely to initiate treatments after diagnosis. We sought to evaluate changes in the treatment initiation of patients newly diagnosed with atrial fibrillation (AF) after the onset of the COVID-19 pandemic. Methods: In this retrospective cohort study, we identified individuals with incident AF from 01/01/2016–09/30/2021 using Optum’s de-identified Clinformatics® Data Mart Database. The primary outcome was initiation of oral anticoagulation (OAC) within 30 days of AF diagnosis. Secondary outcomes included initiation of OAC within 180 days of diagnosis, initiation of warfarin, direct oral anticoagulants (DOACs), rhythm control medications and electrical cardioversion within 30 days of diagnosis. We constructed interrupted time series analyses to examine changes in the outcomes following the onset of the pandemic. Results: A total of 573,524 patients (age 73.0 ± 10.9 years) were included in the study. There were no significant changes in the initiation of OAC, DOAC, and rhythm control medications associated with the onset of the pandemic. There was a significant decrease in initiation of electrical cardioversion associated with the onset of the pandemic. The rate of electronic cardioversion within 30 days of diagnosis decreased by 4.9% per 1,000 patients after the onset of the pandemic and decreased by about 35% in April 2020, compared to April 2019, from 5.53% to 3.58%. Conclusion: The COVID-19 pandemic did not affect the OAC initiation within 30 days of AF diagnosis but was associated with a decline in the provision of procedures for patients newly diagnosed with AF.

4 August 2026 in Journal of the American Heart Association
Verified
Journal Article
Open access
LYLanting Yang
Lanting Yang
NGNico Gabriel
Nico Gabriel
STShangbin Tang
Shangbin Tang
LCLauren Cater
Lauren Cater
Hayley BlackburnHayley Blackburn
Hayley Blackburn
IHInmaculada Hernandez
Inmaculada Hernandez
Background: Residents of western US states face elevated fine particulate matter (PM 2.5 ) exposure from increasingly frequent and intense wildfires, raising concerns about cardiovascular risk. Whether short‐term PM 2.5 exposure increases odds of hospitalization or emergency care in patients with established atrial fibrillation (AF) remains unclear. Methods: Using 2021 Medicare data, we identified patients with established AF residing in western US states. Zip code–level daily PM 2.5 was estimated using a 1 km 2 geospatial model; high PM 2.5 was defined as ≥9.0 μg/m 3 . Odds ratios (ORs) for all‐cause and cardiovascular disease hospitalization and emergency department visits were estimated using conditional logistic regression at lag 0, 1, and 3 days, adjusting for extreme heat and public holidays. Results: The final cohort included 26 158 patients (mean age 79 ± 9.0 years) with established AF. Exposure to high levels of PM 2.5 was associated with 10% (95% CI, 1%–20%) increased odds of hospitalizations for cardiovascular disease. Specifically, high PM 2.5 was associated with 24% (95% CI, 3%–48%) increased odds of hospitalization and 34% (95% CI, 6%–70%) higher odds of emergency department visits for all AF‐related diagnoses. We did not observe significant interaction effects between PM 2.5 and extreme heat on the risk of hospitalization or emergency department visits for cardiovascular disease or AF. Conclusion: On days with elevated PM 2.5 levels, patients with AF were associated with higher odds of AF‐related or cardiovascular hospitalizations and emergency department visits, highlighting the need for targeted prevention strategies to protect vulnerable populations from the adverse effects of air pollution.